Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

In patients with chronic myeloid leukemia (CML), disease in the initial chronic phase (CP) and subsequent progression are driven by the oncogenic activity of the BCR–ABL fusion kinase. Imatinib, a tyrosine kinase inhibitor of BCR–ABL, has been the mainstay of first-line therapy for CML for 10 years....

Ausführliche Beschreibung